The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis

Haematologica

Volumn 93, Issue 10, 2008, Pages 1495-1504

  Nogami, Wataru ^a,b   Yoshida, Hiroshi ^b   Koizumi, Kenzo ^b   Yamada, Hajime ^b   Abe, Kenji ^b   Arimura, Akinori ^b   Yamane, Noriko ^b   Takahashi, Koji ^b   Yamane, Akiko ^a   Oda, Atsushi ^c   Tanaka, Yoshikazu ^b   Takemoto, Hiroshi ^b   Ohnishi, Yasuyuki ^d   Ikeda, Yasuo ^a   Miyakawa, Yoshitaka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

Author keywords

Megakaryocyte; Platelet; Thrombocytopenia; Thrombopoietin; Thrombopoietin receptor

Indexed keywords

AUTOANTIBODY; BUTYZAMIDE; CYTOKINE RECEPTOR AGONIST; RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3; RECOMBINANT THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD34 SELECTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG EFFECT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS;

ANIMALS; ANTIGENS, CD34; BLOOD PLATELETS; CELL DIFFERENTIATION; CELL LINE; CELL MEMBRANE; HUMANS; MEGAKARYOCYTES; MICE; MOLECULAR STRUCTURE; PEPTIDES; PLATELET AGGREGATION; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; THIAZOLES; THROMBOPOIETIN;

EID: 54349089372     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12752     Document Type: Article

References (37)

1. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533-8.
2. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-8.
3. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-71.
4. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, et al. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369:571-4.
5. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77: 1117-24.
6. Vigon I, Mornon JP, Cocault L, Mitjavila MT, Tambourin P, Gisselbrecht S, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992;89:5640-4.
7. Debili N, Wendling F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391-401.
8. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J 1995;14:5569-78.
9. Sasaki K, Odai H, Hanazono Y, Ueno H, Ogawa S, Langdon WY, et al. TPO/c-mpl ligand induces tyrosine phosphorylation of multiple cellular proteins including proto-oncogene products, Vav and c-Cbl, and Ras signaling molecules. Biochem Biophys Res Commun 1995;216:338-47.
10. Drachman JG, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem 1995;270:4979-82.
11. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995;374:48-52.
12. Bacon CM, Tortolani PJ, Shimosaka A, Rees RC, Longo DL, O'Shea JJ. Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3. FEBS Lett 1995;370:63-8.
13. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood 1999;94:1273-82.
14. Miyakawa Y, Rojnuckarin P, Habib T, Kaushansky K. Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem 2001;276:2494-502.
15. Sattler M, Salgia R, Durstin MA, Prasad KV, Griffin JD. Thrombopoietin induces activation of the phosphatidylinositol-3′ kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol 1997;171:28-33.
16. Hong Y, Dumenil D, van der Loo B, Goncalves F, Vainchenker W, Erusalimsky JD. Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl-expressing UT-7 cells. Blood 1998;91:813-22.
17. de Sauvage FJ, Carver-Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996;183:651-6.
18. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994;265:1445-7.
19. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996;87:2162-70.
20. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:3457-69.
21. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-8.
22. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002;99:2599-602.
23. Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990;75:116-21.
24. Yamane N, TanakaY, Ohyabu N, Yamane S, Maekawa K, Ishizaki J, et al. Characterization of novel non-peptide thromobopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor. Eur J Pharmacol 2008;586:44-51.
25. Erickson-Miller CL, Delorme E, Giampa L, Hopson C, Valoret E, Tian SS, et al. Biological activity and selectivity for Tpo receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115. Blood 2004;104:2912a.
26. Nakamura T, Miyakawa Y, Miyamura A, Yamane A, Suzuki H, Ito M, et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood 2006;107:4300-7.
27. Suzuki K, Abe M, Fukushima M, Sugasawa K, Hirayama F, Kawasaki T, et al. YM477, a novel orally-active thrombopoietin receptor agonist. Blood 2005;106:2298a[abstract].
28. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/γ(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175-82.
29. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain(null) mice. Blood 2005;106: 1565-73.
30. Kim MJ, Park SH, Opella SJ, Marsilje TH, Michellys PY, Seidel HM, et al. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem 2007; 282:14253-61.
31. Miyakawa Y, Oda A, Druker BJ, Miyazaki H, Handa M, Ohashi H, et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996;87:439-46.
32. Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996;87:4664-70.
33. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase I clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist. Blood 2007;109:4739-41.
34. Bussel JB, Cheng G, Saleh M, Kovaleva L, Stone N, Mayer B, et al. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): a randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor. Blood 2006;108:475a [abstract].
35. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-81.
36. Kuter DJ, Bussel JB, George JN, Aledort LM, Lichtin AE, Lyons RM, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood 2006;108:476a [abstract].
37. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood 2006;108:477a[abstract].